Skip to content
  • Countries
    • Finland
    • France
    • Germany
    • Greece
    • Italy
    • Ireland
    • Netherlands
    • Poland
    • Spain
    • United Kingdom
  • VPAGs
  • Hospitals
  • Projects
    • Patient Conference 2022
    • Videos Patient Conference
    • Videos Talkshows Dublin
    • FAIRVASC
    • SEE ME. HEAR ME.
    • Rare Revolution Magazine
  • Diseases

    Introduction

    • Vasculitis Classification

    Large Vessel Vasculitis

    • GCA (Giant Cell Arteritis)
    • Takayasu

    Small Vessel Vasculitis

    AAV (ANCA Associated Vasculitis)

    • EGPA
    • GPA
    • MPA

    Immune Complex Vasculitis

    • Cryoglobulinemic Vasculitis
    • IgA vasculitis (Henoch Schönlein)
    • Anti GBM Vasculitis (Goodpasture)
    • Anti C1q vasculitis (hypocomplementic)

    Medium Vessel Vasculitis

    • PAN (Polyarteritis Nodosa)
    • Kawasaki Disease

    Variable Vessel Vasculitis

    • Behçet
    • Cogan Syndrome

    Single Organ Vascilitus

    • Cutaneous Leucoclastic Vasculitis
  • News
  • About Us
    • Contact us
    • Our Mission
    • A Registered Charity

NEWS

What is happening in the world of Vasculitis ?

tintrial
  • Peter Verhoeven
  • februari 19, 2021
  • 4:04 pm

Results ADVOCATE study in NEJM

Today February 18th 2021 the results of an important clinical study were published in the New England Journal of Medicine.


The trial was conducted from March 15, 2017, until November 1, 2019 (last trial visit).


In a phase 3 randomized trial (ADVOCATE) the avacopan product was compared with a tapering schedule of prednisone in patients with ANCA-associated vasculitis concurrently treated with immunosuppressive drugs.


Patients were enrolled at 143 centers in an international, randomized, double-blind, double-dummy, controlled trial. The aim was to evaluate whether avacopan could replace a glucocorticoid-tapering regimen used in the treatment of ANCA-associated vasculitis

Avacopan (30 mg twice daily) or matching placebo was given for 52 weeks, with 8 weeks of follow-up. Prednisone or a matched placebo was given on a tapering schedule for 20 weeks (60 mg per day tapered to discontinuation by week 21)


The conclusion as published was:

In this trial involving patients with ANCA-associated vasculitis, avacopan was noninferior but not superior to prednisone taper with respect to remission at week 26 and was superior to prednisone taper with respect to sustained remission at week 52. All the patients received cyclophosphamide or rituximab. The safety and clinical effects of avacopan beyond 52 weeks were not addressed in the trial.


According to the authors “Longer trials are required to determine the durability and safety of avacopan in patients with ANCA-associated vasculitis,”.

Source NEJM 18th Feb 2021

NextPatient Conference DublinNext

collaborate

join us today 

Do it Now

About us

  • We encourage and support Vasculitis Patient Advocacy Groups (VPAGs) to collaborate and grow stronger.
  • If there is no existing VPAG in a particular country we can  help to create one.
  • We collaborate with any institution willing to help us in achieving these goals.

Find

VPAGs

Hospitals

Countries

Act

Talk to us

Join us

Social Media
Facebook-f Twitter Google-plus-g Youtube Linkedin-in